Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Assets AverageEnterprise ValueEquity AverageEquity RatioInterest Coverage RatioInvested CapitalReturn on AssetsReturn on Capital EmployedReturn on EquityTimes Interest Earned

Allogene Therapeutics (ALLO) Equity Ratio (2019 - 2025)

Allogene Therapeutics (ALLO) has disclosed Equity Ratio for 7 consecutive years, with 0.7 as the latest value for Q4 2025.

  • Quarterly Equity Ratio fell 8.58% to 0.7 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was 0.7 through Dec 2025, down 8.58% year-over-year, with the annual reading at 0.7 for FY2025, 8.58% down from the prior year.
  • Equity Ratio hit 0.7 in Q4 2025 for Allogene Therapeutics, down from 0.72 in the prior quarter.
  • In the past five years, Equity Ratio ranged from a high of 0.91 in Q2 2021 to a low of 0.7 in Q4 2025.
  • Historically, Equity Ratio has averaged 0.81 across 5 years, with a median of 0.8 in 2023.
  • Biggest five-year swings in Equity Ratio: grew 6.67% in 2021 and later decreased 10.79% in 2023.
  • Year by year, Equity Ratio stood at 0.88 in 2021, then fell by 7.81% to 0.81 in 2022, then fell by 1.83% to 0.8 in 2023, then dropped by 3.44% to 0.77 in 2024, then decreased by 8.58% to 0.7 in 2025.
  • Business Quant data shows Equity Ratio for ALLO at 0.7 in Q4 2025, 0.72 in Q3 2025, and 0.73 in Q2 2025.